vs
Side-by-side financial comparison of Ceribell, Inc. (CBLL) and STEM, INC. (STEM). Click either name above to swap in a different company.
STEM, INC. is the larger business by last-quarter revenue ($47.1M vs $24.8M, roughly 1.9× Ceribell, Inc.). STEM, INC. runs the higher net margin — -33.9% vs -54.6%, a 20.7% gap on every dollar of revenue.
Ceribell, Inc. develops and commercializes innovative portable neurodiagnostic medical devices, focused on rapid non-invasive electroencephalogram (EEG) solutions for seizure detection. Its core products serve hospital emergency departments, intensive care units, and long-term care facilities, with primary markets across North America and ongoing global expansion efforts.
StemCells, Inc. is a public biopharmaceutical company headquartered in Newark, California, that is developing purified human neural stem cells (HuCNS-SCs) in the hopes of treating central nervous system disorders and paralysis. StemCells' HuCNS-SCs have the ability to differentiate into the three main types of cells found in the central nervous system: neurons, astrocytes and oligodendrocytes.
CBLL vs STEM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $24.8M | $47.1M |
| Net Profit | $-13.5M | $-16.0M |
| Gross Margin | 87.3% | 48.9% |
| Operating Margin | -58.9% | -17.7% |
| Net Margin | -54.6% | -33.9% |
| Revenue YoY | — | -15.6% |
| Net Profit YoY | — | 68.8% |
| EPS (diluted) | $-0.35 | $-4.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $24.8M | $47.1M | ||
| Q3 25 | $22.6M | $38.2M | ||
| Q2 25 | $21.2M | $38.4M | ||
| Q1 25 | $20.5M | $32.5M | ||
| Q4 24 | — | $55.8M | ||
| Q3 24 | $17.2M | $29.3M | ||
| Q2 24 | — | $34.0M | ||
| Q1 24 | — | $25.5M |
| Q4 25 | $-13.5M | $-16.0M | ||
| Q3 25 | $-13.5M | $-23.8M | ||
| Q2 25 | $-13.6M | $202.5M | ||
| Q1 25 | $-12.8M | $-25.0M | ||
| Q4 24 | — | $-51.1M | ||
| Q3 24 | $-10.4M | $-148.3M | ||
| Q2 24 | — | $-582.3M | ||
| Q1 24 | — | $-72.3M |
| Q4 25 | 87.3% | 48.9% | ||
| Q3 25 | 88.3% | 35.5% | ||
| Q2 25 | 88.1% | 33.4% | ||
| Q1 25 | 87.9% | 32.4% | ||
| Q4 24 | — | -4.4% | ||
| Q3 24 | 87.3% | 21.2% | ||
| Q2 24 | — | 27.6% | ||
| Q1 24 | — | -95.0% |
| Q4 25 | -58.9% | -17.7% | ||
| Q3 25 | -64.8% | -33.6% | ||
| Q2 25 | -70.5% | -34.8% | ||
| Q1 25 | -69.3% | -65.0% | ||
| Q4 24 | — | -84.4% | ||
| Q3 24 | -57.8% | -493.2% | ||
| Q2 24 | — | -1705.5% | ||
| Q1 24 | — | -267.0% |
| Q4 25 | -54.6% | -33.9% | ||
| Q3 25 | -59.6% | -62.2% | ||
| Q2 25 | -64.4% | 527.8% | ||
| Q1 25 | -62.4% | -76.9% | ||
| Q4 24 | — | -91.6% | ||
| Q3 24 | -60.6% | -506.3% | ||
| Q2 24 | — | -1712.6% | ||
| Q1 24 | — | -283.9% |
| Q4 25 | $-0.35 | $-4.40 | ||
| Q3 25 | $-0.37 | $-2.84 | ||
| Q2 25 | $-0.38 | $-1.79 | ||
| Q1 25 | $-0.36 | $-0.15 | ||
| Q4 24 | — | $-15.29 | ||
| Q3 24 | $-1.85 | $-18.24 | ||
| Q2 24 | — | $-71.81 | ||
| Q1 24 | — | $-0.46 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $159.3M | $48.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $155.3M | $-249.4M |
| Total Assets | $195.8M | $308.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $159.3M | $48.9M | ||
| Q3 25 | $168.5M | $43.1M | ||
| Q2 25 | $177.4M | $40.8M | ||
| Q1 25 | $182.7M | $58.6M | ||
| Q4 24 | — | $56.3M | ||
| Q3 24 | $14.1M | $75.4M | ||
| Q2 24 | — | $89.6M | ||
| Q1 24 | — | $112.8M |
| Q4 25 | $155.3M | $-249.4M | ||
| Q3 25 | $164.1M | $-235.7M | ||
| Q2 25 | $172.2M | $-214.1M | ||
| Q1 25 | $180.9M | $-417.5M | ||
| Q4 24 | — | $-398.4M | ||
| Q3 24 | $-136.0M | $-344.1M | ||
| Q2 24 | — | $-203.2M | ||
| Q1 24 | — | $371.6M |
| Q4 25 | $195.8M | $308.9M | ||
| Q3 25 | $199.5M | $362.6M | ||
| Q2 25 | $207.7M | $379.2M | ||
| Q1 25 | $213.5M | $405.1M | ||
| Q4 24 | — | $437.4M | ||
| Q3 24 | $47.1M | $537.8M | ||
| Q2 24 | — | $691.5M | ||
| Q1 24 | — | $1.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-10.8M | $8.2M |
| Free Cash FlowOCF − Capex | $-11.0M | — |
| FCF MarginFCF / Revenue | -44.2% | — |
| Capex IntensityCapex / Revenue | 0.7% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-41.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-10.8M | $8.2M | ||
| Q3 25 | $-11.1M | $11.4M | ||
| Q2 25 | $-7.5M | $-21.3M | ||
| Q1 25 | $-11.4M | $8.5M | ||
| Q4 24 | — | $-14.7M | ||
| Q3 24 | — | $-9.4M | ||
| Q2 24 | — | $-11.9M | ||
| Q1 24 | — | $-621.0K |
| Q4 25 | $-11.0M | — | ||
| Q3 25 | $-11.5M | — | ||
| Q2 25 | $-7.6M | — | ||
| Q1 25 | $-11.6M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -44.2% | — | ||
| Q3 25 | -50.8% | — | ||
| Q2 25 | -35.9% | — | ||
| Q1 25 | -56.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 0.7% | — | ||
| Q3 25 | 1.6% | — | ||
| Q2 25 | 0.3% | — | ||
| Q1 25 | 0.7% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.11× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CBLL
| Products | $18.8M | 76% |
| Subscription | $6.0M | 24% |
STEM
Segment breakdown not available.
